FDA Grants Full Approval Of Tecelra To Children Battling Synovial Sarcoma

The US Food and Drug Administration (FDA) has granted full approval to a cutting-edge cancer medication called Tecelra and expanded its use to include teenagers aged 12 and older. Originally given temporary, accelerated approval in 2024, this treatment is designed for a specific type of rare tissue cancer called synovial sarcoma that has already spread or cannot be removed with surgery. It is a major milestone because it is the first ever “engineered T-cell therapy” (a type of treatment that reprograms a patient’s own immune cells) to get full approval for treating solid tumors, offering a critical new option for teenagers and adults who have already tried standard chemotherapy.

In simple terms, Tecelra works like a highly targeted, living drug. Doctors harvest a patient’s own immune cells, genetically modify them in a lab to recognize a specific protein found inside these cancer cells, and then infuse them back into the patient to hunt down the tumor. Because it is so specialized, patients must have a specific genetic makeup and tumor type to qualify for the treatment, which is given as a single infusion. In clinical trials, the therapy successfully shrank or eliminated tumors in about 44% of patients, providing a major breakthrough for a specific group of patients who previously had very limited treatment options.

Read the full article